Insider Transactions in Q1 2025 at Schrodinger, Inc. (SDGR)
Insider Transaction List (Q1 2025)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Mar 03
2025
|
Geoffrey Craig Porges EVP & CFO |
SELL
Open market or private sale
|
Direct |
5,491
-16.62%
|
$115,311
$21.76 P/Share
|
|
Mar 03
2025
|
Geoffrey Craig Porges EVP & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
27,350
+35.87%
|
-
|
|
Mar 03
2025
|
Robert Lorne Abel Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+37.75%
|
-
|
|
Mar 03
2025
|
Yvonne Tran EVP, CLO & CPO |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+34.59%
|
-
|
|
Mar 03
2025
|
Kenneth Patrick Lorton EVP, CTO & COO, Software |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+18.92%
|
-
|
|
Mar 03
2025
|
Jenny Herman SVP & Controller |
BUY
Grant, award, or other acquisition
|
Direct |
9,800
+25.92%
|
-
|
|
Mar 03
2025
|
Margaret Dugan Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
12,500
+32.49%
|
-
|
|
Mar 03
2025
|
Ramy Farid President & CEO |
BUY
Grant, award, or other acquisition
|
Direct |
37,500
+14.45%
|
-
|
|
Mar 03
2025
|
Karen Akinsanya President of R&D, Therapeutics |
BUY
Grant, award, or other acquisition
|
Direct |
15,625
+50.0%
|
-
|
|
Feb 18
2025
|
Yvonne Tran EVP, CLO & CPO |
SELL
Open market or private sale
|
Direct |
3,902
-25.95%
|
$109,256
$28.0 P/Share
|
|
Feb 18
2025
|
Yvonne Tran EVP, CLO & CPO |
BUY
Exercise of conversion of derivative security
|
Direct |
3,902
+20.6%
|
$15,608
$4.34 P/Share
|
|
Feb 11
2025
|
Yvonne Tran EVP, CLO & CPO |
SELL
Open market or private sale
|
Direct |
828
-6.92%
|
$19,872
$24.43 P/Share
|
|
Feb 11
2025
|
Jenny Herman SVP & Controller |
SELL
Open market or private sale
|
Direct |
859
-4.5%
|
$20,616
$24.43 P/Share
|
|
Feb 11
2025
|
Kenneth Patrick Lorton EVP, CTO & COO, Software |
SELL
Open market or private sale
|
Direct |
985
-2.34%
|
$23,640
$24.43 P/Share
|
|
Feb 10
2025
|
Robert Lorne Abel Officer |
SELL
Open market or private sale
|
Direct |
1,225
-13.12%
|
$30,625
$25.99 P/Share
|